Clinical trial · Interventional
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
NCT00452673CI-TRIAL-00017218completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- 50 mg BID dasatinib + 825 mg/m^2 BID capecitabine
- description
- Twice a day (BID) for 2 weeks of a 3-week cycle
- interventionNames
- Drug: Dasatinib
- Drug: Capecitabine
- type
- EXPERIMENTAL
- label
- 70 mg BID dasatinib + 825 mg/m^2 BID capecitabine
- description
- BID for 2 weeks of a 3-week cycle
- interventionNames
- Drug: Dasatinib
- Drug: Capecitabine
- type
- EXPERIMENTAL
- label
- 70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Inclusion Criteria: * Female with advanced breast cancer previously treated with a taxane and an anthracycline * No pleural or pericardial effusion * Not receiving anticoagulants
References
Publications (0)
Data not yet available
No reference posted for this study.